FERTICSIMolecule for Improved Live Birth Rates After ICSI in Women Under 37

This clinical trial aims to explore a new method to improve the chances of having a live birth after a procedure called ICSI, which is commonly used in France to help with fertilization. The study involves adding a special peptide to the fluid that surrounds the egg cells and developing embryos during certain stages of the process. This approach is designed to help the eggs divide their chromosomes better and to support the growth of embryos in a lab setting. The study specifically targets women under the age of 37, as younger eggs tend to have better outcomes, hoping to increase the live birth rate after the first embryo transfer. In this study, participants are divided randomly into two groups. In the treated group, after the eggs are retrieved, they are prepared by removing the outer layer and then are incubated with a special molecule before undergoing the ICSI process. The developing embryos are then also exposed to this molecule until they reach the blastocyst stage. In the control group, the eggs and embryos are treated similarly, but without the special molecule. The trial measures success by looking at how many live births occur after the first embryo transfer, with only one high-quality embryo being transferred at a time. This careful process aims to assess whether the addition of the peptide can lead to better outcomes for couples undergoing ICSI.